Quotient (NASDAQ:QTNT) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of Quotient (NASDAQ:QTNT) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning, Zacks.com reports.

According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “

Separately, BidaskClub lowered shares of Quotient from a buy rating to a hold rating in a research note on Friday, May 15th.

QTNT stock opened at $7.61 on Tuesday. The company has a current ratio of 4.83, a quick ratio of 4.17 and a debt-to-equity ratio of 9.74. Quotient has a 1 year low of $2.39 and a 1 year high of $11.30. The company has a fifty day simple moving average of $7.61 and a 200 day simple moving average of $7.06. The firm has a market cap of $607.61 million, a PE ratio of -5.25 and a beta of 2.66.

Quotient (NASDAQ:QTNT) last released its quarterly earnings data on Tuesday, June 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.03. The business had revenue of $8.70 million during the quarter, compared to analyst estimates of $7.80 million. As a group, analysts forecast that Quotient will post -1.39 EPS for the current fiscal year.

In other Quotient news, COO Edward Farrell sold 12,811 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $7.40, for a total transaction of $94,801.40. Following the completion of the transaction, the chief operating officer now owns 29,013 shares of the company’s stock, valued at approximately $214,696.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jeremy Stackawitz sold 11,000 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $7.41, for a total transaction of $81,510.00. Following the transaction, the insider now directly owns 142,926 shares of the company’s stock, valued at approximately $1,059,081.66. The disclosure for this sale can be found here. 14.20% of the stock is owned by insiders.

Several large investors have recently bought and sold shares of QTNT. State Street Corp increased its holdings in shares of Quotient by 10.7% during the 4th quarter. State Street Corp now owns 112,817 shares of the company’s stock worth $1,073,000 after purchasing an additional 10,880 shares during the period. Raymond James & Associates bought a new position in shares of Quotient during the 4th quarter worth about $104,000. Credit Suisse AG increased its holdings in shares of Quotient by 46.4% during the 4th quarter. Credit Suisse AG now owns 2,443,068 shares of the company’s stock worth $23,234,000 after purchasing an additional 774,814 shares during the period. Trexquant Investment LP bought a new position in shares of Quotient during the 4th quarter worth about $294,000. Finally, Renaissance Technologies LLC bought a new stake in Quotient in the fourth quarter valued at about $207,000. Institutional investors own 76.50% of the company’s stock.

Quotient Company Profile

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.

Recommended Story: Why investors pay attention to retained earnings

Get a free copy of the Zacks research report on Quotient (QTNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.